[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 381,251
  • Shares Outstanding, K 103,883
  • Annual Sales, $ 0 K
  • Annual Income, $ -165,670 K
  • EBIT $ -172 M
  • EBITDA $ -174 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 154.45% (+9.78%)
  • Historical Volatility 91.18%
  • IV Percentile 18%
  • IV Rank 8.29%
  • IV High 765.22% on 06/03/26
  • IV Low 99.27% on 03/12/26
  • Expected Move (DTE 35) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 847
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 27,175
  • Open Int (30-Day) 25,865
  • Expected Range 3.71 to 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 5
  • High Estimate $-0.31
  • Low Estimate $-0.48
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) +4.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.92 +26.88%
on 06/29/26
4.32 -14.24%
on 07/10/26
+0.16 (+4.66%)
since 06/17/26
3-Month
2.92 +26.88%
on 06/29/26
4.84 -23.37%
on 04/21/26
-1.10 (-22.81%)
since 04/17/26
52-Week
2.71 +36.46%
on 02/23/26
6.42 -42.29%
on 02/25/26
+0.38 (+11.60%)
since 07/17/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR).  Such investors...

LRMR : 3.67 (+0.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK   , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR).  Such investors...

LRMR : 3.67 (+0.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are...

LRMR : 3.67 (+0.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are...

LRMR : 3.67 (+0.27%)
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp...

LRMR : 3.67 (+0.27%)
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company...

LRMR : 3.67 (+0.27%)
Larimar: Q1 Earnings Snapshot

Larimar: Q1 Earnings Snapshot

LRMR : 3.67 (+0.27%)
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second...

LRMR : 3.67 (+0.27%)
Will Larimar Therapeutics Finally Prove Its Friedreich's Ataxia Therapy Deserves the Valuation?

Barchart Research What to Expect from LRMR Earnings LRMR Generated May 12, 2026 Current Price $4.13 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.86% Will Larimar Therapeutics Finally...

LRMR : 3.67 (+0.27%)
Larimar Therapeutics: The Safety Narrative Wall Street Accepted May Not Survive This Quarter

Barchart Research What to Expect from LRMR Earnings LRMR Generated May 5, 2026 Current Price $4.01 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.86% Larimar Therapeutics: The Safety Narrative...

LRMR : 3.67 (+0.27%)

Business Summary

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

See More

Key Turning Points

3rd Resistance Point 4.07
2nd Resistance Point 3.93
1st Resistance Point 3.80
Last Price 3.67
1st Support Level 3.54
2nd Support Level 3.40
3rd Support Level 3.27

See More

52-Week High 6.42
Fibonacci 61.8% 5.00
Fibonacci 50% 4.57
Fibonacci 38.2% 4.13
Last Price 3.67
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.